Drilldown: Medicines

Adalimumab (1) · Famotidine (1) · Hydrochlorothiazide (1)

Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada (1) · Microzide; mostly prescribed generically (1) · Pepcid, Pepcid AC, Pepcid Complete (1)

[[:Category:Antihypertensives|Antihypertensive]] (1) · [[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) · [[:Category:Biologics|Biologic]] (1) · [[:Category:DMARDs|DMARD]] (1) · [[:Category:H2_receptor_antagonists|Histamine H2 receptor antagonist]] (1) · [[:Category:Immunosuppressants|Immunosuppressant]] (1) · [[:Category:Monoclonal_antibodies|Monoclonal antibody (fully human IgG1)]] (1) · [[:Category:Thiazide_diuretics|Thiazide diuretic]] (1) · [[:Category:TNF_inhibitors|TNF-α inhibitor]] (1)

'"`UNIQ--vote-00000138-QINU`"' Decreases urinary calcium (used in stone prevention); raises serum uric acid, glucose, and lipids modestly; non-anion-gap hypokalemic metabolic alkalosis is the characteristic electrolyte pattern'"`UNIQ--ref-00000139-QINU`"'. (1) · '"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1) · '"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1)

None (1) · '"`UNIQ--vote-0000013A-QINU`"', '"`UNIQ--vote-0000013B-QINU`"', '"`UNIQ--vote-0000013C-QINU`"', '"`UNIQ--vote-0000013D-QINU`"' (1) · '"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"' (1)

12.5-25 mg PO once daily (1) · 20 mg PO twice daily, or 40 mg at bedtime (1) · 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1)

10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) · 12.5 mg capsules; 12.5, 25, 50 mg tablets (1) · 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1)

160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications (1) · 40 mg every week (selected indications); otherwise 40 mg every other week (1) · 50 mg/d (hypertension); up to 200 mg/d (edema) (1)

IV (1) · Oral (2) · Subcutaneous (1)

1 hour PO; minutes IV (1) · Diuresis at 2 hours; antihypertensive effect within days, max at 3-4 weeks (1) · Symptomatic effect within weeks; full response by 12-24 weeks (1)

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) · 6-15 hours'"`UNIQ--ref-0000013E-QINU`"' (1) · ~14 days'"`UNIQ--ref-00001103-QINU`"' (1)

40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"' (1) · 65-75% (oral)'"`UNIQ--ref-0000013F-QINU`"' (1) · ~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1)

None (2) · Generally considered safe; widely used. Cleared in lactation at low levels.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (1) · OTC (10-20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) · [[USLegal:Prescription only|Rx-only]] in US (1)